{
    "clinical_study": {
        "@rank": "14895", 
        "arm_group": {
            "arm_group_label": "Avastin regimens", 
            "description": "Patients who have either received or who are going to receive chemotherapy plus Avastin (bevacizumab)"
        }, 
        "brief_summary": {
            "textblock": "Investigators propose to assess, retrospectively (from 1/7/2009) and prospectively (up to\n      31/12/2013,) the safety and tolerability profile (number of participants with adverse\n      events) of standard chemotherapy and anti-angiogenic agent bevacizumab (Avastin) as first\n      line treatment of patients with metastatic Colorectal Cancer with or without KRAS mutation.\n      All treatment schedules that are going to be assessed are considered by the international\n      guidelines as standard therapy for patients with metastatic Colorectal Cancer."
        }, 
        "brief_title": "Assessment of Clinical Practice Administration of Chemotherapy and Anti-angiogenic Agent (Bevacizumab) in Colorectal Cancer", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Metastatic Colorectal Cancer", 
        "condition_browse": {
            "mesh_term": "Colorectal Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "In addition investigators propose to assess the compliance of patients to treatment and the\n      efficacy of treatment. That means percentage of objective responses, duration of response,\n      frequency of curative liver resection after the administration of treatment, progression\n      free survival and estimation of overall survival"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Written informed consent\n\n          -  Histologically confirmed metastatic or locally advanced non-operable colorectal\n             cancer\n\n          -  No prior first line treatment for metastatic colorectal cancer\n\n          -  Age \u226518 years\n\n          -  One or more measurable lesions (\u22651cm in diameter with spiral CT scan or \u22652cm    with\n             conventional techniques) according to RECIST criteria\n\n          -  ECOG performance status \u22642\n\n          -  Adequate haematological, renal and hepatic function\n\n          -  Urine protein <2+ (dipstick)\n\n          -  Life expectancy of \u226512 weeks\n\n        Exclusion Criteria:\n\n          -  Previous first line treatment for metastatic colorectal cancer(progression >6 months\n             after the end of adjuvant treatment)\n\n          -  Previous radiotherapy to target lesions\n\n          -  Patients with brain metastases and/or cancerous meningitis\n\n          -  Metastatic infiltration >50% of the liver parenchyma\n\n          -  Presence or history of other neoplasm except properly treated basal cell skin cancer\n             or in situ cervical carcinoma\n\n          -  Patients participating in interventional clinical trial"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Clinics for cancer prevention"
            }
        }, 
        "enrollment": {
            "#text": "600", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 21, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01811108", 
            "org_study_id": "CT/10.12"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Angiogenesis Inhibitors", 
                "Bevacizumab"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "mCRC", 
            "KRAS mutation", 
            "Chemotherapy", 
            "Anti-angiogenic agent", 
            "Bevacizumab", 
            "1st Line"
        ], 
        "lastchanged_date": "September 13, 2013", 
        "location": [
            {
                "contact": {
                    "email": "evamaragoud@gmail.com", 
                    "last_name": "Eva Maragkoudaki", 
                    "phone": "+302810392570"
                }, 
                "facility": {
                    "address": {
                        "city": "Heraklion", 
                        "country": "Greece", 
                        "state": "Crete"
                    }, 
                    "name": "University Hospital of Crete, Dep of Medical Oncology"
                }, 
                "investigator": {
                    "last_name": "Ioannis Souglakos, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Stylianos Kakolyris, MD"
                }, 
                "contact_backup": {
                    "last_name": "Nikolaos Xenidis, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Alexandroupolis", 
                        "country": "Greece"
                    }, 
                    "name": "University General Hospital of Alexandroupolis, Dept. of Medical Oncology"
                }, 
                "investigator": {
                    "last_name": "Stelios Kakolyris, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "nikos251@yahoo.gr", 
                    "last_name": "Nikos Fytrakis", 
                    "phone": "2107715690"
                }, 
                "facility": {
                    "address": {
                        "city": "Athens", 
                        "country": "Greece"
                    }, 
                    "name": "Air Forces Military Hospital of Athens"
                }, 
                "investigator": {
                    "last_name": "Nikos Kentepozidis, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Stylianos Giassas, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Athens", 
                        "country": "Greece"
                    }, 
                    "name": "\"IASO\" General Hospital of Athens"
                }, 
                "investigator": {
                    "last_name": "Stylianos Giassas, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Nikolaos Ziras, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Piraeus", 
                        "country": "Greece"
                    }, 
                    "name": "\"Metaxa's\" Anticancer Hospital of Piraeus, 1st Dep of Medical Oncology"
                }, 
                "investigator": {
                    "last_name": "Nikolaos Ziras, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Ioannis Mpoukovinas, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Thessaloniki", 
                        "country": "Greece"
                    }, 
                    "name": "\"Theagenion\" Anticancer Hospital of Thessaloniki, 2nd Dep of Medical Oncology"
                }, 
                "investigator": {
                    "last_name": "Ioannis Mpoukovinas, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Greece"
        }, 
        "number_of_groups": "1", 
        "official_title": "Assessment of Clinical Practice Administration of Chemotherapy and Anti-angiogenic Agent (Bevacizumab) Retrospectively (From 1/7/2009) and Prospectively (up to 31/12/2013) as First Line Treatment for Patients With Locally Advanced or Metastatic Colorectal Cancer (With or Without KRAS Mutation). Assessment of Toxicity, Compliance and Survival of Patients.", 
        "overall_contact": {
            "email": "georgulv@otenet.gr", 
            "last_name": "Vassilis Georgoulias, MD", 
            "phone": "+302810392750"
        }, 
        "overall_official": {
            "affiliation": "Hellenic Oncology Research Group", 
            "last_name": "Vassilis Georgoulias, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Greece: National Organization of Medicines", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "In this observational study investigators are going to assess standard schedules  in which administration was every 2 weeks.", 
            "measure": "Number of Participants with AE", 
            "safety_issue": "Yes", 
            "time_frame": "Every 2 weeks up to 12 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01811108"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "In this observational study investigators are going to assess standard schedules in which the disease evaluation was performed every 6 weeks", 
                "measure": "Number of Participants with Response Rate", 
                "safety_issue": "No", 
                "time_frame": "Disease evaluation at Week 6"
            }, 
            {
                "measure": "Percentage of Patients with Progression Free Survival", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "measure": "Patients Overall Survival", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }
        ], 
        "source": "Hellenic Oncology Research Group", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hellenic Oncology Research Group", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2009", 
        "study_design": "Observational Model: Cohort", 
        "study_type": "Observational", 
        "verification_date": "September 2013"
    }
}